Efficacy and Safety of MEDI3506 in Adult Subjects with Atopic Dermatitis

Trial Identifier: D9182C00001
Sponsor: AstraZeneca
NCTID:: NCT04212169
Start Date: December 2019
Primary Completion Date: July 2022
Study Completion Date: September 2022
Condition: Eczema

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
German Translation
English (Australian) Translation
Spanish Translation
Polish Translation

Trial Locations

Country Location
AU Box Hill, AU, 3128
AU Carlton, AU, 3053
AU East Melbourne, AU, 3002
AU Fremantle, AU, 6160
DE Berlin, DE, 10117
DE Dresden, DE, 01307
DE Hamburg, DE, 20246
DE Mahlow, DE, 15831
ES Alcobendas, ES, 28100
ES Leganés, ES, 28915
ES Sevilla, ES, 41003
GB Corby, GB, NN18 9EZ
GB High Wycombe, GB, HP11 2QW
GB Kenilworth, GB, CV8 1JD
GB Northwood, GB, HA6 2RN
GB Romford, GB, RM1 3PJ
GB Shipley, GB, BD18 3SA
GB Sidcup, GB, DA14 6LT
GB Wokingham, GB, RG40 1XS
PL Bialystok, PL, 15-453
PL Kielce, PL, 25-355
PL Łódź, PL, 90-436
PL Poznan, PL, 60-681
PL Skierniewice, PL, 96-100
PL Wroclaw, PL, 50-566
US, AL Birmingham, AL, US, 35209
US, CA Santa Monica, CA, US, 90404
US, FL Jacksonville, FL, US, 32256
US, FL Miami, FL, US, 33180
US, FL Orlando, FL, US, 32806
US, LA Baton Rouge, LA, US, 70808
US, NC Charlotte, NC, US, 28277
US, OK Tulsa, OK, US, 74136
US, RI Providence, RI, US, 02903
US, SC Spartanburg, SC, US, 29303
US, TN Memphis, TN, US, 38119
US, TX San Antonio, TX, US, 78213
US, TX San Antonio, TX, US, 78229